Abologix Sàrl

ABOLOGIX develops novel therapeutics in oncology. The company´s lead program is a monoclonal antibody (code-named H-225) for the treatment of several sub-types of non-Hodgkin´s lymphoma (NHL), specifically Mantle Cell Lymphoma (MCL), a disease of very poor prognosis. H-225 blocks the function of JAM-C, a cell adhesion molecule involved in the transmigration of lymphocytes out of the tissues and into the blood stream. In preclinical in vivo animal models ABOLOGIX has shown that treatment with H-225 leads to a a dramatic increase in overall survival. The next steps are the humanization of H-225 (in progress) and testing the potential of the molecule in Phase I/IIa clinical trials. We then intend to license / sell H-225 to a large pharma company for further development and commercialization